Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02155192 · ClinicalTrials.gov registry record
An Exploratory Genetic Study in Participants With Psoriasis
A clinical trial, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 712
- Enrollment target
NCT02155192 is a clinical trial that has completed, run by Janssen Research & Development. The registered enrollment target is 712 participants.
The verdict
NCT02155192 has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 712 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the association between genetic factors and response to treatment (guselkumab, ustekinumab, adalimumab, or etanercept) and psoriasis (scaly skin rash).
Interventions
- DRUG No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 712 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02155192
The ClinicalTrials.gov registry entry for NCT02155192 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 712 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT02155192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02155192 about?
NCT02155192 is a clinical study titled "An Exploratory Genetic Study in Participants With Psoriasis". The purpose of this study is to evaluate the association between genetic factors and response to treatment (guselkumab, ustekinumab, adalimumab, or etanercept) and psoriasis (scaly skin rash).
What is the current status of trial NCT02155192?
This trial is currently completed. The enrollment target is 712 participants. The study started on 2014-03. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02155192?
The interventions under investigation include: No Intervention (DRUG).
Who is sponsoring clinical trial NCT02155192?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.